Trial · NCT05729282
Glycemic Effect of Diazoxide in NAFLD
NCT05729282, Phase 1, Completed, Columbia University
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Glycemic Effect of Diazoxide in NAFLD. Trials, record NCT05729282. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05729282
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Glycemic Effect of Diazoxide in NAFLD
- NCT number
- NCT05729282
- Status
- Completed
- Phases
- Phase 1
- Enrollment
- 22 participants, actual
- Lead sponsor
- Columbia University
- Conditions
- Hyperinsulinemia, Insulin Resistance, Non-Alcoholic Fatty Liver Disease, Prediabetic State
- Interventions
- Diazoxide oral suspension, 1 mg per kg per dose, Diazoxide oral suspension, 2 mg per kg per dose, Placebo, FreeStyle Libre Pro, Deuterated water (2H2O/D2O)
- First posted
- 2023-02-15
- Last updated
- 2026-09-30
Source ClinicalTrials.gov
Registered outcomes15
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Fasting Plasma Glucose (Absolute Values) | Up to Study Day 15 | Measurement of fasting plasma glucose levels during treatment with diazoxide 1 mpk vs 2 mpk vs placebo (units: mg/dL). |
| Primary | Fasting Plasma Glucose (Fold Change) | Up to Study Day 15 | Measurement of fasting plasma glucose during treatment with diazoxide 1 mpk vs 2 mpk vs placebo (units: fold change in mg/dL from baseline). |
| Primary | Fasting Plasma/Serum Insulin (Absolute Values) | Up to Study Day 15 | Measurement of fasting endogenous insulin levels during treatment with diazoxide 1 mpk vs 2 mpk vs placebo (units: micro-international units \[µIU\] per mL). |
| Primary | Fasting Plasma/Serum Insulin (Fold Change) | Up to Study Day 15 | Measurement of fasting endogenous insulin levels during treatment with diazoxide 1 mpk vs 2 mpk vs placebo (units: fold change in µIU/mL from baseline). |
| Secondary | Fasting Serum or Plasma Triglycerides (TG) (Absolute Values) | Up to Study Day 15 | Measurement of fasting circulating TG during treatment with diazoxide 1 mpk vs 2 mpk vs placebo (units: mg/dL). |
| Secondary | Fasting Serum/Plasma Triglycerides (TG) (Fold Change) | Up to Study Day 15 | Measurement of fasting serum TG during treatment with diazoxide 1 mpk vs 2 mpk vs placebo (units: fold change in mg/dL from baseline). |
| Secondary | Fasting Plasma Free Fatty Acids (FFA) (Absolute Values) | Up to Study Day 15 | Measurement of fasting plasma FFA (units: mmol/L) during treatment with diazoxide 1 mpk vs 2 mpk vs placebo |
| Secondary | Fasting Plasma Free Fatty Acids (FFA) (Fold Change) | Up to Study Day 15 | Measurement of fasting serum FFA during treatment with diazoxide 1 mpk vs 2 mpk vs placebo (units: fold change in mmol/L from baseline) |
| Secondary | Fasting Serum/Plasma Apolipoprotein B (ApoB) (Absolute Values) | Up to Study Day 15 | Measurement of fasting serum/plasma ApoB during treatment with diazoxide 1 mpk vs 2 mpk vs placebo (units: mg/dL) |
| Secondary | Fasting Serum/Plasma Apolipoprotein B (ApoB) (Fold Change) | Baseline and 2 weeks post-treatment | Measurement of fasting serum/plasma ApoB during treatment with diazoxide 1 mpk vs 2 mpk vs placebo (units: fold change in mg/dL from baseline). |
1 to 10 of 15Source ClinicalTrials.gov
See all 15 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| K12DK133995 | Diabetes-Docs: Physician-Scientist Career Development Program (DiabDocs) | MAAHS, DAVID MATTHEW; DIMEGLIO, LINDA A | STANFORD UNIVERSITY | NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES | 2022 to 2025 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05729282
GET https://conductscience.org/api/trials/v1/NCT05729282/registered